ストックスクリーナーアプリを入手
15.01
3.47%
-0.54
アフターアワーズ：
14.90
-0.11
-0.73%
前日終値:
$15.55
開ける：
$15.8
24時間の取引高:
420.94K
Relative Volume:
0.99
時価総額：
$931.06M
収益：
-
当期純損益:
$-41.43M
株価収益率:
-19.00
EPS:
-0.79
ネットキャッシュフロー:
$-39.97M
1週間 パフォーマンス:
+13.37%
1か月 パフォーマンス:
+4.89%
6か月 パフォーマンス:
-3.04%
1年 パフォーマンス:
+67.15%
1日の値動き範囲:
$14.71
$15.84
1週間の範囲:
$13.50
$19.00
52週間の値動き範囲:
$7.98
$20.50
Gh Research Plc Stock (GHRS) Company Profile
GHRS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
15.01 | 964.56M | 0 | -41.43M | -39.97M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-13 | 開始されました | Needham | Buy |
| 2025-06-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-13 | 開始されました | Guggenheim | Buy |
| 2025-03-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-02-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-08-16 | 開始されました | H.C. Wainwright | Buy |
| 2022-06-16 | 開始されました | ROTH Capital | Buy |
すべてを表示
Gh Research Plc (GHRS) 最新ニュース
EBIT per share of GH Research Plc – FWB:1KA - TradingView — Track All Markets
GH Research PLC (GHRS) Stock Analysis: 109.70% Upside Potential Amid Promising Biotech Innovations - DirectorsTalk Interviews
Wall Street Analysts Think GH Research (GHRS) Could Surge 130.59%: Read This Before Placing a Bet - MSN
Will GH Research PLC (1KA) stock profit from fiscal stimulusStability vs Neutral Overview & lightweight options for faster days - ulpravda.ru
Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December - Sahm
Assessing GH Research (GHRS) Valuation After FDA Lifts Clinical Hold On GH001 IND - Sahm
Is GH Research PLC (1KA) stock protected from inflationTrade Ideas & Low Risk Entry Point Tips - ulpravda.ru
Why analysts maintain buy rating on GH Research PLC (1KA) stock2025 Market Overview & Low Risk Profit Maximizing Plans - ulpravda.ru
Risk Analysis: How institutional buying supports GH Research PLC stockTrend Reversal & High Accuracy Investment Entry Signals - ulpravda.ru
Published on: 2026-01-09 02:32:55 - ulpravda.ru
GH Research PLCOrdinary Shares (NQ: GHRS - FinancialContent
What dividend safety score for GH Research PLC stockEarnings Risk Report & Low Risk High Reward Trade Ideas - ulpravda.ru
How strong is GH Research PLC stock balance sheet2025 Valuation Update & Weekly High Conviction Ideas - ulpravda.ru
Quarterly Recap: What dividend safety score for GH Research PLC stock2025 Top Gainers & Weekly High Conviction Trade Ideas - ulpravda.ru
GH Research to Present Six-Month Safety and Efficacy Data on Inhaled GH001 in Depression at 2026 ACNP Meeting - TipRanks
Why is GHRS stock rising today? - MSN
Assessing GH Research (GHRS) Valuation After FDA Lifts Clinical Hold On GH001 Trials - Yahoo Finance UK
Stock market today: S&P 500, Nasdaq futures rise, WTI fluctuates following US strike on Venezuela—GH Research, Vertiv Holdings, Nukkleus in focus - MSN
Why Is GHRS Stock Rising Today? - Asianet Newsable
What drives GH Research PLC stock priceDividend Reinvestment Plans & Outstanding Capital Tips - earlytimes.in
Stock Ratings | HC Wainwright & Co. maintained its "buy" rating on MetaVia Inc. (MTVA) shares and raised its price target from $12 to $40, representing a potential upside of 393.83%. - Sahm
Will GH Research PLC (1KA) stock gain from green policies2026 world cup usa national team round of 32 playmakers pressing system odds analysis tactical review - ulpravda.ru
GH Research (NASDAQ:GHRS) Stock Price Down 9.2%Should You Sell? - MarketBeat
GH Research stock price target raised to $29 from $19 at Needham - Investing.com Nigeria
GH Research stock price target raised to $29 from $19 at Needham By Investing.com - Investing.com South Africa
GH Research stock rises as FDA lifts clinical hold on GH001 - Investing.com Australia
GH Research stock jumps as Canaccord raises price target on FDA hold lift - Investing.com
GHRS Stock Sees Significant Price Target Increase by Needham | G - GuruFocus
GH Research (GHRS) Is Up 24.2% After FDA Lifts Hold On GH001 U.S. Trial Enrollment - simplywall.st
Hold lifted, as GH Research preps for pivotal GH-001 depression trial - BioWorld MedTech
GH Research stock rating reiterated as Buy by TD Cowen - Investing.com Nigeria
GH Research says FDA lifts clinical hold on GH001 - TipRanks
GH Research stock rises as FDA lifts clinical hold on inhaled 5-MeO-DMT By Investing.com - Investing.com South Africa
GH Research (NASDAQ:GHRS) Shares Gap UpTime to Buy? - MarketBeat
GH Research stock rises as FDA lifts clinical hold on inhaled 5-MeO-DMT - Investing.com Australia
GH Research stock rises as Stifel reiterates Buy rating after clinical hold lifted By Investing.com - Investing.com South Africa
Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
US Stocks Higher; Dow Jumps 250 Points - Benzinga
GH Research stock rises as Stifel reiterates Buy rating after clinical hold lifted - Investing.com Nigeria
Why Is GH Research Stock Soaring Monday?GH Research (NASDAQ:GHRS) - Benzinga
Why GH Research Is Rising In Pre-market? - Nasdaq
Stock Market Today: S&P 500, Nasdaq, WTI Crude Futures Advance After US Strike On Venezuela— GH Research, Vertiv Holdings, Nukkleus In Focus (UPDATED) - Benzinga
Stock Market Today: S&P 500, Nasdaq, WTI Crude Futures Advance After US Strike On Venezuela— GH Research, Vertiv Holdings, Nukkleus In Focus (UPDATED) - Benzinga
Wondering what's happening in today's pre-market session? - Chartmill
Gh Research shares jump 44% premarket after US FDA lifts clinical hold on depression drug trials - MarketScreener
GHRS: Needham Reiterates Buy Rating and $19 Price Target | GHRS Stock News - GuruFocus
GH Research surges as FDA lifts clinical hold (GHRS:NASDAQ) - Seeking Alpha
GH Research (NASDAQ:GHRS) Receives Buy Rating from Needham & Company LLC - MarketBeat
GH Research Says FDA Lifted Clinical Hold on Investigational New Drug Application for GH001; Shares Rise Pre-Bell - marketscreener.com
GH Research Wins FDA Clearance to Advance GH001 for Treatment-Resistant Depression - TipRanks
GH Research stock soars after FDA lifts clinical hold on GH001 By Investing.com - Investing.com South Africa
Gh Research Plc (GHRS) 財務データ
収益
当期純利益
現金流量
EPS
0.90%
大文字化:
|
ボリューム (24 時間):